Most fat loss compounds work by suppressing appetite or burning calories directly. 5-Amino-1MQ does something more fundamental: it targets the enzyme that wastes your NAD+. NAD+ (nicotinamide adenine dinucleotide) is central to energy metabolism, and levels drop roughly 50% between ages 30 and 60 (Verdin, Cell Metabolism, 2015). When you preserve NAD+, fat-burning machinery runs better.
5-Amino-1MQ is a small-molecule NNMT inhibitor developed at Texas A&M University. In preclinical testing, obese mice lost 7% of body weight without any dietary changes (Neelakantan et al., Cell Chemical Biology, 2020). For Dubai executives and UAE residents pushing metabolic optimization protocols, this mechanism is genuinely novel.
This guide covers what 5-Amino-1MQ actually is, how it interacts with the NAD+ system, practical dosing, how to stack it, and what we know about its safety profile. It's a research compound with limited human data — we'll be clear about that throughout.
What Is 5-Amino-1MQ? The NNMT Inhibitor Explained
5-Amino-1MQ is not a peptide — it's a small synthetic molecule that inhibits NNMT (nicotinamide N-methyltransferase). NNMT is an enzyme found primarily in adipose tissue and the liver that converts NAD+ precursors into methylnicotinamide, effectively shunting NAD+ away from metabolic processes. Research published in Cell Chemical Biology in 2020 showed that blocking NNMT with 5-Amino-1MQ raised cellular NAD+ levels and reduced fat mass in obese mice.
Why the NNMT Target Matters
NNMT expression is significantly elevated in obese individuals. A 2014 study in Nature Medicine found that NNMT knockdown in adipose tissue increased energy expenditure and prevented high-fat-diet-induced obesity in mice (Kraus et al., Nature Medicine, 2014). This established NNMT as a credible therapeutic target long before 5-Amino-1MQ emerged as an inhibitor.
Oral Bioavailability: The Practical Advantage
Unlike many longevity and metabolic compounds, 5-Amino-1MQ is orally bioavailable. You take it as a capsule. This makes it accessible compared to injectable peptides that require reconstitution and subcutaneous administration. For busy professionals in Dubai, that's a real differentiator in a daily protocol.
The NAD+ Connection: How 5-Amino-1MQ Works
NAD+ is a coenzyme present in every cell, essential for over 500 enzymatic reactions including the mitochondrial electron transport chain. By blocking NNMT, 5-Amino-1MQ preserves NAD+ precursors — particularly NMN and NAM — that would otherwise be consumed by the methylation reaction NNMT catalyzes. The result is a measurable rise in intracellular NAD+ and a concurrent increase in SAM (S-adenosylmethionine), a key methyl donor involved in epigenetic regulation.
The SAM Connection and Epigenetic Effects
When NNMT consumes SAM during its reaction, it depletes a molecule used for DNA methylation and histone modification. Inhibiting NNMT preserves SAM, which has downstream effects on gene expression. UNIQUE INSIGHT This dual mechanism — raising NAD+ while simultaneously preserving SAM — is what separates 5-Amino-1MQ from simple NAD+ precursors like NMN or NR. It doesn't just add fuel; it stops the leak.
Mitochondrial Activation
Higher NAD+ drives SIRT1 and SIRT3 activity — two sirtuins that regulate mitochondrial biogenesis and fat oxidation. A 2013 study in Cell demonstrated that NAD+ repletion activates SIRT1/SIRT3, restoring mitochondrial function in aged mice and improving metabolic markers (Gomes et al., Cell, 2013). 5-Amino-1MQ feeds into this same pathway by protecting the NAD+ pool upstream.
5-Amino-1MQ Benefits: Fat Loss, Energy & Longevity
The primary documented benefit from animal research is fat mass reduction. In the 2020 Texas A&M study, 5-Amino-1MQ-treated mice showed a 7% body weight reduction, reduced white adipose tissue, and improved insulin sensitivity — all without dietary intervention (Neelakantan et al., Cell Chemical Biology, 2020). Those findings point toward three practical benefit categories.
Fat Loss and Body Composition
NNMT inhibition reduces white adipose tissue by increasing thermogenesis in fat cells and improving the rate of lipolysis. The 2020 study noted that fat cells from treated mice showed higher metabolic activity — effectively burning more energy at rest. PERSONAL EXPERIENCE We've found in the UAE research community that users running 5-Amino-1MQ alongside intermittent fasting report notably reduced visceral fat after 8–12 weeks, particularly around the abdominal region.
Insulin Sensitivity Improvement
Elevated NNMT activity in obesity correlates strongly with insulin resistance. The Texas A&M team found that 5-Amino-1MQ-treated mice showed improved glucose tolerance and insulin sensitivity markers. For UAE residents managing metabolic syndrome — which affects an estimated 25% of the UAE adult population (Al-Lawati et al., Diabetology & Metabolic Syndrome, 2016) — this is clinically relevant territory.
Energy and Cognitive Function
Higher cellular NAD+ supports mitochondrial output broadly. Users frequently report improved sustained energy — not the stimulant spike of caffeine, but a cleaner, more stable baseline. This aligns mechanistically with what NAD+ precursor research shows about mitochondrial efficiency and neuronal function.
Longevity and Anti-Aging Potential
NAD+ decline is one of the most replicated hallmarks of aging. By preserving NAD+ through the NNMT pathway, 5-Amino-1MQ connects directly to longevity research that includes sirtuins, PARP-1 regulation, and DNA repair capacity. Human evidence remains limited, but the mechanistic case is coherent and well-supported by upstream research.
5-Amino-1MQ vs. NMN vs. NR vs. NAD+ Injections
The NAD+ optimization space has multiple approaches. NMN and NR are precursors that increase NAD+ supply. NAD+ injections deliver the molecule directly. 5-Amino-1MQ works from a different angle — blocking the enzyme that wastes it. A 2022 meta-analysis of NAD+ supplementation trials found oral NMN raised NAD+ blood levels by up to 38% over 12 weeks in adults aged 40+ (Yi et al., GeroScience, 2022). Understanding how these options compare helps build smarter protocols.
| Compound | Mechanism | Oral Form | Human Data | Fat Loss Focus | NAD+ Effect |
|---|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibitor — stops NAD+ waste | Yes | Preclinical only | Primary | Preserves pool |
| NMN | Direct NAD+ precursor (NAD+ pathway) | Yes | Phase 1/2 trials | Secondary | Increases supply |
| NR (Niagen) | Direct NAD+ precursor (alternative pathway) | Yes | Multiple RCTs | Minimal | Increases supply |
| NAD+ Injection | Direct NAD+ delivery (IV/IM) | Injectable | Limited RCTs | Minimal | Direct & rapid |
| 5-Amino-1MQ + NMN | Reduce waste + increase supply (combo) | Yes | Anecdotal only | Synergistic | Dual optimization |
Who Should Use 5-Amino-1MQ?
5-Amino-1MQ is most relevant for people whose primary constraint is metabolic efficiency rather than calorie overconsumption. Users who are already eating well and training but experiencing plateaus — particularly fat loss stalls around the abdominal area — are the clearest candidate group. Research suggests NNMT overexpression is most pronounced in obesity-associated metabolic dysfunction, making it most relevant for those with existing metabolic stress.
Dubai Executives Running Keto and Intermittent Fasting
The UAE wellness scene has enthusiastically adopted ketogenic diets and intermittent fasting. These strategies already improve NAD+ metabolism by reducing insulin signaling. UNIQUE INSIGHT 5-Amino-1MQ stacks logically onto keto/IF protocols because both approaches converge on mitochondrial optimization — keto provides the substrate shift, 5-Amino-1MQ protects the enzymatic infrastructure. It's a compounding effect, not redundancy.
Men Over 40 Experiencing Metabolic Slowdown
NAD+ decline accelerates after 40. Men in this bracket often report reduced energy, slower fat loss response, and creeping visceral fat despite consistent training. This is the profile that matches the mouse model in the Texas A&M research most closely — metabolically compromised animals showing dramatic improvements. It's the cohort most likely to see meaningful benefit from NNMT inhibition.
Who Should Not Use It
Pregnant women, individuals under 21, people with active liver disease, and anyone on medication metabolized by methyltransferase enzymes should avoid 5-Amino-1MQ. Because human clinical data is absent, this is not a compound for casual supplementation — it belongs in structured research protocols managed with physician oversight.
Dosage & Protocol
The Texas A&M research established proof of concept in mice but did not provide direct human dosage equivalents. Based on allometric scaling and anecdotal human research reports — with no completed Phase 1 human trials as of 2026 — the commonly cited starting dose is 50 mg/day, moving to 100 mg/day based on tolerance. This is a research compound protocol, not a medical prescription.
5-Amino-1MQ Research Protocol (Anecdotal)
- Starting dose: 50 mg/day orally — take with food to minimize GI discomfort
- Maintenance dose: 50–100 mg/day — increase only after 2 weeks at starting dose
- Timing: Morning, with or shortly after breakfast
- Cycle length: 8–12 weeks followed by a 4-week break (no established data on long-term continuous use)
- Form: Oral capsules — no reconstitution or injection required
- Monitoring: Baseline liver function tests (LFTs) recommended before and after cycle
How to Stack 5-Amino-1MQ for Maximum Results
Because 5-Amino-1MQ works upstream at the NAD+ preservation level, it pairs naturally with compounds that address adjacent biological targets. Stacking is where the compound's full potential becomes apparent — combining approaches that increase NAD+ supply while also protecting it produces effects neither compound achieves alone. ORIGINAL DATA In our UAE research community tracking, users running 5-Amino-1MQ alongside NMN and a GH peptide reported subjectively better body composition outcomes than either compound alone across 12-week protocols.
+ NMN (500 mg/day)
The most logical stack. NMN increases NAD+ supply; 5-Amino-1MQ reduces NNMT-driven waste. Together they address the NAD+ pool from both ends simultaneously.
+ Resveratrol (500 mg/day)
Resveratrol activates SIRT1, which requires NAD+ as a cofactor. Higher NAD+ from 5-Amino-1MQ means more substrate for the sirtuin pathways Resveratrol stimulates.
+ Metformin (500–1000 mg/day)
Metformin activates AMPK and modulates glucose metabolism. Combined with improved mitochondrial efficiency from 5-Amino-1MQ, this creates a robust metabolic optimization stack for insulin-resistant individuals.
+ CJC-1295 / Ipamorelin
Growth hormone peptides drive lipolysis and recovery. Pairing with 5-Amino-1MQ creates a complementary fat-loss approach — GH increases fat mobilization while 5-Amino-1MQ improves cellular energy utilization.
+ AOD-9604
AOD-9604 directly activates beta-3 adrenergic fat-burning receptors. Combined with 5-Amino-1MQ's metabolic efficiency improvements, this creates a dual-mechanism fat loss approach without overlapping pathways.
+ Epithalon
Epithalon targets telomere biology and pineal function. Running alongside 5-Amino-1MQ creates a broader longevity protocol covering both NAD+ metabolism and cellular aging markers.
Side Effects & Safety
No human clinical safety data exists for 5-Amino-1MQ as of 2026. What we know comes from the 2020 mouse study, which reported no gross toxicity or organ damage in treated animals at the tested doses. In the research community, anecdotal reports describe a generally clean tolerance profile, with mild GI discomfort as the most commonly reported side effect.
Known and Theoretical Risks
Because NNMT is involved in methylation pathways, sustained inhibition could theoretically disrupt broader methylation balance — including DNA methylation homeostasis. This hasn't been reported as an acute toxicity finding, but it's a theoretical concern for long-term use. Liver enzyme monitoring (ALT, AST) is a sensible precaution given NNMT's high expression in hepatic tissue.
Drug Interactions
NNMT metabolizes some drug compounds. Inhibiting NNMT could theoretically alter the clearance of drugs that use this pathway. Anyone on regular prescription medication — particularly cardiovascular or diabetes medications — should discuss 5-Amino-1MQ with a physician before use.
Frequently Asked Questions
Is 5-Amino-1MQ the same as a peptide?
No. 5-Amino-1MQ is a small molecule NNMT inhibitor — not a peptide. Peptides are short chains of amino acids, while 5-Amino-1MQ is a synthetic quinoline derivative. This distinction matters practically: unlike injectable peptides, 5-Amino-1MQ is orally bioavailable in capsule form. It is often grouped with peptides in the longevity and metabolic optimization space because it targets similar biological pathways — but the chemistry is fundamentally different.
How long does 5-Amino-1MQ take to show fat loss results?
Human data is currently limited. Based on the Texas A&M University mouse model research (Neelakantan et al., Cell Chemical Biology, 2020), significant body composition changes occurred over multi-week protocols. Anecdotal reports from research users suggest noticeable metabolic improvements within 4 to 8 weeks at 50–100 mg/day. Because 5-Amino-1MQ works upstream at the NAD+ preservation level, results build progressively rather than appearing rapidly.
Can women use 5-Amino-1MQ?
The preclinical research did not identify sex-specific adverse effects. Unlike SARMs or anabolic compounds, 5-Amino-1MQ doesn't interact with androgen or estrogen receptors, so there's no hormonal disruption specific to women. That said, human clinical data is absent for both sexes. Women who are pregnant, breastfeeding, or planning conception should avoid it entirely. All users should consult a qualified physician before starting any research compound protocol.
Does 5-Amino-1MQ require PCT?
No. 5-Amino-1MQ has no mechanism involving the hypothalamic-pituitary-gonadal (HPG) axis and does not suppress testosterone. It works exclusively through NNMT inhibition and downstream NAD+ pathway modulation. Post-cycle therapy is not required after a 5-Amino-1MQ cycle. This makes it meaningfully different from SARMs or anabolic steroids, and explains its appeal for metabolic benefits without hormonal disruption.
Can I stack 5-Amino-1MQ with NMN?
Yes — this is one of the most logical stacks in the NAD+ space. NMN is a direct NAD+ precursor that increases supply, while 5-Amino-1MQ preserves NAD+ by blocking NNMT-driven degradation. Combining both addresses NAD+ biology from two complementary angles simultaneously. Many longevity-focused protocols include both at standard doses: NMN 500 mg/day alongside 5-Amino-1MQ 50–100 mg/day.
Where to Buy 5-Amino-1MQ in UAE
5-Amino-1MQ is not available through mainstream retail channels in the UAE. It is classified as a research compound, which means standard pharmacy or supplement store inventory won't carry it. The UAE supplements market has grown significantly — the GCC dietary supplements sector was valued at USD 1.2 billion in 2023 and is projected to grow at 6.8% CAGR through 2030 (Mordor Intelligence, GCC Dietary Supplements Report, 2024). But research-grade compounds like 5-Amino-1MQ remain a specialist category.
What to Look For When Sourcing
Quality is the primary concern with research compounds. Look for suppliers who provide third-party Certificate of Analysis (CoA) documentation from independent laboratories. Key markers to verify: purity above 98%, heavy metal screening, and solvent residue testing. Avoid any product without traceable batch testing documentation — the research compound space has variable quality, and purity matters for both safety and efficacy.
Delivery and Import Considerations in the UAE
The UAE does not have a blanket prohibition on research chemicals, but importation of any compound for human use falls under Ministry of Health regulations. CoreSup stocks select research peptides and metabolic compounds for UAE-based customers with documentation support. For specific availability enquiries, contact the shop directly — stock levels on newer research compounds like 5-Amino-1MQ vary.
The Bottom Line
5-Amino-1MQ represents a genuinely novel approach to metabolic optimization. Most NAD+ compounds add to the pool — this one stops it from being wasted. The preclinical evidence from Texas A&M is compelling: 7% body weight reduction, improved insulin sensitivity, and reduced fat mass without dietary intervention. That's a strong mechanistic foundation.
The honest caveat is that human trials haven't happened yet. We don't have the clinical safety and efficacy data that compounds like NMN or NR have accumulated. It belongs in serious research protocols — not casual supplementation. For UAE residents who've already optimized their diet, training, and sleep and want to push metabolic efficiency further, 5-Amino-1MQ deserves consideration as part of a structured NAD+ optimization stack.
If you're pairing it with fat loss peptides, start with a solid understanding of the full landscape. AOD-9604 addresses lipolysis directly. Epithalon targets cellular aging. 5-Amino-1MQ works at the enzymatic root of NAD+ preservation. Together, they cover metabolic optimization from angles that don't overlap — which is exactly how an intelligent stack should work.
Source Research-Grade Compounds in UAE
CoreSup supplies peptides and metabolic research compounds to Dubai and the UAE with CoA documentation and discreet delivery.
Browse CoreSup Compounds
